Clinicopathological and Prognostic Value of USP22 Expression in Gastric Cancer: A Systematic Review and Meta-Analysis and Database Validation

Overview

Journal Front Surg

Specialty General Surgery

Date 2022 Jul 5

PMID 35784926

Authors

Yuhang Wang

Zirui Jia

Jiacheng Gao

Tingting Zhou

Xiangwen Zhang

Guo Zu

Affiliations

Soon will be listed here.

Abstract

Background: It has been reported that there is a correlation between the level of ubiquitin-specific protease 22 (USP22) and the clinicopathological parameters and prognosis of gastric cancer (GC) patients, but the conclusions are inconsistent. Hence, a meta-analysis must be conducted to clarify the relationship between USP22 expression and clinicopathological and prognostic value of GC patients to provide more accurate evidence.

Methods: According to the predetermined selection criteria, systematic file retrieval was performed. The hazard ratio (HR) or odds ratio (OR) and its 95% confidence interval (CI) were used to evaluate the relationship between USP22 expression and clinicopathological and prognostic value of GC patients.

Results: In a total of 802 patients, those with GC were finally included in 6 studies. The pooled results demonstrated that the expression of USP22 was significantly increased in GC tissues compared with control tissues (OR = 9.947, 95% CI, 6.074-16.291, = 0.000), and USP22 expression was related to lymph node metastasis (OR = 2.415, 95% CI, 1.082, = 0.031), distant metastasis (OR = 3.956, 95% CI, 1.365-11.464, = 0.011) and TNM stage (OR = 2.973, 95% CI, 1.153-7.666, = 0.024). Nevertheless, the expression of USP22 was not correlated with gender (OR = 1.202, 95% CI, 0.877-1.648, = 0.253), age (OR = 1.090, 95% CI, 0.811-1.466, = 0.568), tumor size (OR = 0.693,95% CI, 0.348-1.380, = 0.297), tumor differentiation (OR = 1.830, 95%CI, 0.948-3.531, = 0.072) and depth of invasion (OR = 2.320, 95% CI, 0.684-7.871, = 0.177). Moreover, a high expression of USP22 predicted a poor overall survival (OS) in GC patients (HR = 2.012, 95% CI, 1.522-2.658, = 0.000). The database of Kaplan-Meier plotter confirmed that a high expression of USP22 was correlated with poor prognostics in GC patients (HR = 1.41, 95% CI, 1.18-1.68, < 0.01).

Conclusion: USP22 overexpression in GC tissues is positively related to lymph node metastasis, distant metastasis and TNM stage and indicates a poor clinical outcome of GC patients, but it is not associated with age, gender, depth of invasion, tumor differentiation and tumor size of GC patients.: https://www.crd.york.ac.uk/prospero/, identifier: 338361.

Citing Articles

Research Progress for Targeting Deubiquitinases in Gastric Cancers.

An T, Lu Y, Gong Z, Wang Y, Su C, Tang G Cancers (Basel). 2022; 14(23).

PMID: 36497313 PMC: 9735992. DOI: 10.3390/cancers14235831.

as a STAD Prognostic Biomarker Associated with Immune Infiltration.

Xiao C, Yang L, Jin L, Zhang F, Liu J, Yu C Diagnostics (Basel). 2022; 12(10).

PMID: 36292195 PMC: 9600629. DOI: 10.3390/diagnostics12102506.

References

Han B, Sun Y, Yang D, Zhang H, Mo S, Chen X . USP22 promotes development of lung adenocarcinoma through ubiquitination and immunosuppression. Aging (Albany NY). 2020; 12(8):6990-7005. PMC: 7202522. DOI: 10.18632/aging.103056. View

Zhang X, Varthi M, Sykes S, Phillips C, Warzecha C, Zhu W . The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell. 2008; 29(1):102-11. PMC: 2254522. DOI: 10.1016/j.molcel.2007.12.015. View

Glinsky G . Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin.... Cell Cycle. 2006; 5(11):1208-16. DOI: 10.4161/cc.5.11.2796. View

Arnold M, Abnet C, Neale R, Vignat J, Giovannucci E, McGlynn K . Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology. 2020; 159(1):335-349.e15. PMC: 8630546. DOI: 10.1053/j.gastro.2020.02.068. View

Li J, Wang Z, Li Y . USP22 nuclear expression is significantly associated with progression and unfavorable clinical outcome in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2012; 138(8):1291-7. DOI: 10.1007/s00432-012-1191-5. View

Liu H, Liu N, Zhao Y, Zhu X, Wang C, Liu Q . Oncogenic USP22 supports gastric cancer growth and metastasis by activating c-Myc/NAMPT/SIRT1-dependent FOXO1 and YAP signaling. Aging (Albany NY). 2019; 11(21):9643-9660. PMC: 6874452. DOI: 10.18632/aging.102410. View

Liu Y, Yang Y, Xu H, Dong X . Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer. J Gastroenterol Hepatol. 2010; 25(11):1800-5. DOI: 10.1111/j.1440-1746.2010.06352.x. View

Lv L, Xiao X, Gu Z, Zeng F, Huang L, Jiang G . Silencing USP22 by asymmetric structure of interfering RNA inhibits proliferation and induces cell cycle arrest in bladder cancer cells. Mol Cell Biochem. 2010; 346(1-2):11-21. DOI: 10.1007/s11010-010-0585-4. View

Zheng H, Yu J, Li W, Yang D, Gao C, Zhang Q . Is co-expression of USP22 and HSP90 more effective in predicting prognosis of gastric cancer?. Pathol Res Pract. 2019; 215(4):653-659. DOI: 10.1016/j.prp.2018.12.020. View

10.

Ma Y, Fu H, Wang Z, Huang H, Ni J, Song J . USP22 maintains gastric cancer stem cell stemness and promotes gastric cancer progression by stabilizing BMI1 protein. Oncotarget. 2017; 8(20):33329-33342. PMC: 5464871. DOI: 10.18632/oncotarget.16445. View

11.

Roedig J, Kowald L, Juretschke T, Karlowitz R, Abhari B, Roedig H . USP22 controls necroptosis by regulating receptor-interacting protein kinase 3 ubiquitination. EMBO Rep. 2020; 22(2):e50163. PMC: 7857539. DOI: 10.15252/embr.202050163. View

12.

Kim D, Hong A, Park H, Shin W, Yoo L, Jeon S . Deubiquitinating enzyme USP22 positively regulates c-Myc stability and tumorigenic activity in mammalian and breast cancer cells. J Cell Physiol. 2017; 232(12):3664-3676. DOI: 10.1002/jcp.25841. View

13.

Glinsky G, Berezovska O, Glinskii A . Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005; 115(6):1503-21. PMC: 1136989. DOI: 10.1172/JCI23412. View

14.

Piao S, Ma J, Wang W, Liu Y, Zhang M, Chen H . Increased expression of USP22 is associated with disease progression and patient prognosis of salivary duct carcinoma. Oral Oncol. 2013; 49(8):796-801. DOI: 10.1016/j.oraloncology.2013.03.454. View

15.

Zhibo Q, Lianxin L . Ubiquitin-specific protease 22 is associated with poor prognosis in neuroblastoma. Adv Clin Exp Med. 2020; 29(3):295-300. DOI: 10.17219/acem/115089. View

16.

Schrecengost R, Dean J, Goodwin J, Schiewer M, Urban M, Stanek T . USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. Cancer Res. 2013; 74(1):272-86. PMC: 3947329. DOI: 10.1158/0008-5472.CAN-13-1954. View

17.

Li Z, Yu Y, Du C, Fu H, Wang J, Tian Y . RNA interference-mediated USP22 gene silencing promotes human brain glioma apoptosis and induces cell cycle arrest. Oncol Lett. 2013; 5(4):1290-1294. PMC: 3629196. DOI: 10.3892/ol.2013.1188. View

18.

Sitarz R, Skierucha M, Mielko J, Offerhaus G, Maciejewski R, Polkowski W . Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018; 10:239-248. PMC: 5808709. DOI: 10.2147/CMAR.S149619. View

19.

Yang X, Zang H, Luo Y, Wu J, Fang Z, Zhu W . High expression of USP22 predicts poor prognosis and advanced clinicopathological features in solid tumors: a meta-analysis. Onco Targets Ther. 2018; 11:3035-3046. PMC: 5973323. DOI: 10.2147/OTT.S148662. View

20.

Prokakis E, Dyas A, Grun R, Fritzsche S, Bedi U, Kazerouni Z . USP22 promotes HER2-driven mammary carcinoma aggressiveness by suppressing the unfolded protein response. Oncogene. 2021; 40(23):4004-4018. PMC: 8195738. DOI: 10.1038/s41388-021-01814-5. View